EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
Open Access
- 1 February 2014
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 167 (2) , 210-217
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertensionDrug Design, Development and Therapy, 2012
- Bloodstream Infections in Patients With Pulmonary Arterial Hypertension Treated With Intravenous Prostanoids: Insights From the REVEAL REGISTRY®Mayo Clinic Proceedings, 2012
- Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and dilutedDrug Design, Development and Therapy, 2012
- How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?International Journal Of Clinical Practice, 2010
- Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertensionEuropean Respiratory Journal, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medicationsHealth and Quality of Life Outcomes, 2009
- N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Disease Severity in a Heterogeneous Group of Patients With Chronic Precapillary Pulmonary HypertensionThe American Journal of Cardiology, 2006
- Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary HypertensionChest, 2006